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Abstract 
Thromboembolism is a serious complication of induction therapy for childhood acute 
lymphoblastic leukemia. We prospectively compared efficacy and safety of antithrombotic 
interventions in the consecutive leukemia trials ALL-BFM 2000 and AIEOP-BFM ALL 2009. 
Patients with newly diagnosed acute lymphoblastic leukemia (n=949, age 1 to 18 years) were 
randomized to receive low-dose unfractionated heparin, prophylactic low-molecular-weight 
heparin (enoxaparin) or activity-adapted antithrombin throughout induction therapy. Primary 
objective was to test whether enoxaparin or antithrombin reduce the incidence of 
thromboembolism as compared to unfractionated heparin. Principal safety outcome was 
hemorrhage; leukemia outcome was a secondary endpoint. Thromboembolism occurred in 
42 patients (4.4%). Patients assigned to unfractionated heparin had a higher risk of 
thromboembolism (8.0%) compared with those randomized to enoxaparin (3.5%; P=0.011) or 
antithrombin (1.9%; P<0.001). The proportion of patients who refused antithrombotic 
treatment as allocated was 3% in the unfractionated heparin or antithrombin, and 33% in the 
enoxaparin arm. Major hemorrhage occurred in eight patients (no differences between the 
groups). 5-year-event free survival was 80.9±2.2% if assigned to antithrombin compared to 
85.9±2.0% in the unfractionated heparin (P=0.06), and 86.2±2.0% in the enoxaparin group 
(P=0.10). In conclusion, prophylactic use of antithrombin or enoxaparin significantly reduced 
thromboembolism. Despite the considerable number of patients rejecting the assigned 
treatment with subcutaneous injections, the result remains nonambiguous. 
Thromboprophylaxis - for the present time primarily with enoxaparin - can be recommended 
for children and adolescents with acute lymphoblastic leukemia during induction therapy. 
Whether and how antithrombin may affect leukemia outcome remains to be determined.  
 
247 words (abstract) 
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Introduction 
Thromboembolism (TE) is a serious complication of glucocorticoid and E. coli asparaginase-
containing induction therapy for childhood acute lymphoblastic leukemia (ALL). Reported 
incidences vary between 1 and 37%, depending on study design and definition of 
thrombosis, as well as diagnostic, supportive and therapeutic methods.1-6 Acquired 
antithrombin deficiency as a result of asparaginase-induced asparagine depletion is 
considered to be a crucial mechanism for the development of TE during ALL induction 
therapy. The presence of a central venous catheter (CVC) seems to be an additional – at 
least local – risk factor for TE as a significant proportion of TE during ALL treatment is related 
to an indwelling CVC. Furthermore, the risk of TE has been shown to be associated with 
CVC location and insertion technique.1,5,7-12 Published data also provide good evidence for 
adolescent age to be an important risk factor for TE whereas the additional impact of 
inherited thrombophilia has been discussed controversially in the context of childhood ALL 
treatment.5,13-16  
Sufficiently powered randomized trials on thromboprophylaxis in children during ALL 
induction therapy have not been available,16-23 and evidence for the benefit of specific 
thromboprophylactic measures has therefore been lacking so far. In the absence of valid 
medical standards of care regarding thromboprophylaxis and the use of a CVC during ALL 
induction, various different approaches existed in the pediatric cancer centers in Switzerland 
and Germany in the early 2000s, each based on individual experiences and institutional 
standards. This unsatisfactory situation gave the impetus to initiate the THROMBOTECT 
trial, a prospective randomized study to evaluate the efficacy and safety of antithrombotic 
prophylaxis in children treated for ALL. 
As drug administration through an indwelling CVC provides significant gain in comfort for the 
patients and increases the safety of therapy with tissue-toxic agents, the THROMBOTECT 
study was initially designed to include patients with implanted CVC from the initiation of the 
induction phase and was only later on also opened for patients without CVC. Two 
mechanisms of action to prevent TE were utilized in the two interventional arms of the trial: 
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inhibition of thrombin through inactivation of the coagulation factor X by the treatment with 
low-molecular weight heparin (LMWH) enoxaparin (ClexaneTM) and replacement of 
antithrombin by the plasma-derived antithrombin preparation KyberninTM to compensate for 
asparaginase-related aquired antithrombin deficiency. Being aware of the published data of 
Nowak-Göttl et al., that reported an almost 50% incidence of TE among ALL patients with a 
prothrombotic defect, and considering the additional risk factor of an indwelling CVC, a 
control arm without any intervention appeared difficult to justify.15 The third arm therefore 
included continuous infusion of low-dose unfractionated heparin (UFH) while the CVC was in 
use, with the aim to locally prevent clot formation at the tip of the catheter and hereby 
preventing thrombotic occlusion of the indwelling CVC, without reaching relevant systemic 
anticoagulatory effects.7,24-27 Therefore, the low-dose UFH was considered the control arm. 
The current report presents the clinical results of the THROMBOTECT study with respect to 
the incidence of symptomatic TE and hemorrhage as primary efficacy and safety outcomes 
as well as the secondary safety outcome of leukemia-related survival. 
 
Methods 
Study Design  
THROMBOTECT was an open-label, prospective, randomized, multicenter study to evaluate 
two different preventive antithrombotic measures during induction chemotherapy in children 
with ALL treated according to ALL-BFM 2000 (NCT 00430118) and AIEOP-BFM-ALL 2009 
treatment protocols (NCT 01117441). THROMBOTECT was an add on-study to the ALL-
BFM protocols and approved by the leading ethics committees of the Medical School 
Hannover, Germany, and St. Gallen, Switzerland, and by the local ethics committees of each 
participating site. Written informed consent was obtained from guardians and/or patients 
before randomization. The detailed study protocol is available online with the supplemental 
material. 
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Patient eligibility 
Patients were eligible if treated on the ALL-BFM 2000 or AIEOP-BFM ALL 2009 protocol28-30 
and having a CVC inserted by day 8 of induction and remaining in place at least until day 33. 
The choice of the CVC and its maintenance was at the treating physician’s discretion 
according to institutional guidelines. In August 2004, the protocol was amended to allow 
participation of patients without CVC. Exclusion criteria were known hemorrhagic disorders 
unrelated to leukemia, active gastrointestinal ulcer, previous cerebrovascular accident and/or 
known hypersensitivity to heparin.  
 
Randomization and Study Treatment  
After written informed consent had been given, randomization was performed by day 8 in a 
1:1:1 ratio using permuted blocks of 6 patients and stratified by country and the 
glucocorticoid preparation (dexamethasone or prednisone) administered during induction.29 
Randomization was centrally performed by the ALL-BFM study coordination center using 
computer-generated random number lists. This ensured that the participating centers had no 
access to the allocation sequence. The assigned arm was submitted to the centre by fax. 
Patients were randomly assigned to receive one of the two experimental thromboprophylactic 
treatments with either LMWH enoxaparin or with activity-adjusted antithrombin or to the 
control arm low-dose unfractionated heparin (UFH).  
Thromboprophylaxis was started on day 8 and ended on day 33 of induction chemotherapy 
(Figure S1 in the Supplementary Appendix). The observation period covered the induction 
and consolidation phase (Figure S2 in the Supplementary Appendix) up to and including 
protocol day 64.  
Patients in the enoxaparin group received ClexaneTM at 80-100 IU/kg body weight once daily 
subcutaneously31-34 with a target anti-Xa level not exceeding 0.4 U/l, measured 4 hours after 
the third or fourth injection. On days with lumbar puncture or other invasive procedures, 
enoxaparin was postponed until at least 4 hours after the procedure. In the case of 
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thrombocytopenia <30 x 109/L, platelet tranfusion was required or enoxaparin had to be held 
until platelet regeneration.  
In the antithrombin group, antithrombin activity was measured every three days prior to each 
asparaginase administration. If activity was below the lower limit of normal of 80%, the 
plasma-derived antithrombin preparation KyberninTM was substituted calculating the dose 
according to the formula [antithrombintarget 100% – antithrombinactual] x kg body weight targeting 
at 100% AT activity.  
Patients assigned to the control arm received UFH at 2 IU/kg body weight/hour as long as an 
infusion drip was running to locally prevent thrombotic occlusion of the indwelling CVC.24  
Treatment with coagulation factors or anticoagulants beyond the interventions intended per 
protocol was not allowed unless clinically indicated. Management of TE was at the discretion 
of the treating physician. 
Outcome Measures 
Diagnosis of TE was based upon clinical suspicion and had to be confirmed by one or more 
suitable imaging methods within routine diagnostic work-up (Table S1 in the Supplementary 
Appendix). No systematic provision was made for blinding the attending physicians or 
radiologists to the randomization arm. Intermittent dysfunction of the CVC by a clot at the tip 
of the catheter was not considered a thrombotic event as long as CVC patency was restored. 
The principal safety outcome was absence of bleeding complications during the study period. 
The definition of major and minor hemorrhage met internationally defined standards (Table 
S2 in the Supplementary Appendix).35-37 Secondary safety outcomes were event-free survival 
(EFS) and overall survival (OS). EFS was defined as time from diagnosis to the date of last 
follow-up or first event. Events were resistance to therapy, leukemia relapse, secondary 
neoplasm or death from any cause. Failure to achieve remission due to early death or 
resistance was considered as event at time zero. Survival was defined as time from 
diagnosis to the date of last follow-up or death from any cause.  
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Statistical Analysis 
The primary objective was to test whether antithrombotic prophylaxis with enoxaparin or 
antithrombin was superior to UFH. The null hypothesis was that there was no difference 
between enoxaparin or antithrombin versus UFH tested with one-tailed Fisher’s exact test at 
a significance level of P=0.025 each. The main analysis was by intention-to-treat (ITT). In 
order to reach a power of 85% with a significance level of 0.025, 315 patients had to be 
randomized per group, assuming an event rate of 9% within the UFH group and 3% in the 
two interventional groups, respectively. If both comparisons were significantly different, the 
thrombosis rates in the enoxaparin and antithrombin arm had to be tested for equivalence 
(secondary objective). Antithrombin replacement and enoxaparin therapy would be 
considered equivalent if the two-sided 95% confidence interval (95%-CI) of the incidence 
difference did not exceed ±4%. For the equivalence test, patients were analyzed according to 
the given treatment (as treated).  
The Kaplan-Meier method38 was used to estimate survival rates, and differences were 
compared with the log-rank test.39 Cox proportional hazards model was used in univariate 
and multivariate survival analyses.40 Cumulative incidence functions for competing events 
were constructed by the method of Kalbfleisch and Prentice41 and compared with the Gray’s 
test.42 Odds ratios were calculated to compare the risks of thromboembolic events. Except 
for the confirmative analyses of the primary study question, all other analyses were 
exploratory. 
 
Results 
Patient Characteristics 
From December 1st, 2002, to December 31st, 2011, 1526 patients with ALL treated at one of 
the 26 study centers in Germany and Switzerland were eligible for randomization (Figure 1). 
Of these, 577 patients were not randomized, the vast majority because patients and/or 
parents refused consent to be randomized for the enoxaparin arm as they strictly did not 
wish to accept a daily subcutaneous injection. 949 patients (ITT population) were randomly 
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assigned to receive either UFH (N=312), enoxaparin (N=317) or antithrombin (N=320). 
Randomized and non-randomized eligible patients did not differ with respect to their initial 
patient characteristics (Table S3 in the Supplementary Appendix). The proportion of patients 
with poor response to the prednisone prephase (prednisone poor-responders) and slow 
treatment response as assessed by minimal residual disease was significantly higher in the 
group of non-randomized patients. In the ITT population, numbers and characteristics of 
patients were well balanced between the three randomization arms except for a slight 
imbalance in the age distribution with fewer children below six years in the enoxaparin group 
(Table 1). Patient characteristics were evenly distributed between the randomization arms as 
treated except for a significantly lower proportion of patients below 6 years of age in the 
enoxaparin arm (details provided in Table S4 in the Supplementary Appendix). 
The proportion of patients who refused antithrombotic treatment as allocated was 3% in 
patients randomized to UFH (10/312) or antithrombin (11/320), and 33% (105/317) in those 
assigned to enoxaparin (Figure 1). Rejection of the enoxaparin arm was more frequent in 
patients below six years of age than in older patients (62/157 [39%] vs. 42/160 [27%]) with a 
preferential switch to UFH in the younger cohort (Table S5 in the Supplementary Appendix). 
Based on this finding additional exploratory analyses with respect to TE rate and leukemia-
related outcomes were therefore performed, stratified by age and in the as-treated groups. 
Thromboembolic Events 
Among the 949 randomized patients, 42 thromboembolic events were observed (4.4%; 95%-
CI 3.2 to 5.9). Of those, 20 events (47.6%) occurred in the upper, seven (16.7) in the lower 
deep venous system, and 13 (30.9%) in the cerebral sinus veins; two patients (4.8%) had a 
cerebral arterial stroke. Eight of the 42 TEE (19%) were distant to the site of the CVC. Thirty-
three events occurred between treatment day 9 and 36 during induction therapy, nine events 
between treatment day 37 and 52 of induction consolidation.  
Children below six years of age had a significantly lower risk of TE (14/512, 2.7%) than those 
aged 6 to 9 years (11/188, 5.9%) or 10 years and older (17/249, 6.8%; P=0.018). Other 
patient characteristics and features, such as gender, initial white blood cell count, 
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immunophenotype or treatment response did not influence the incidence of TE (data not 
shown). 
The incidence of TE was significantly higher in patients randomized to UFH (25/312; 8.0%) 
than in the enoxaparin (11/317; 3.5%; P=0.011) or antithrombin group (6/320; 1.9%; 
P<0.001). The as-treated analysis revealed an incidence of 6.7% in the UFH group (25/372) 
compared to 3.2% in the enoxaparin (7/216; P=0.089) and 2.6% in the antithrombin group 
(9/341; P=0.013). The respective cumulative incidences are depicted in Figures 2A and B. 
The difference between TE incidences in the enoxaparin and antithrombin group as treated 
was -0.6%; the lower and upper limit of the 95%-CI were -3.5% and +2.3%, respectively (p-
values for the corresponding one sided tests P=0.01 and P=0.001). Thus, antithrombin and 
enoxaparin were equally effective. 
Exploratory as-treated analyses stratified by age (Figures 2D and F) demonstrated a 
significantly reduced risk of TE in patients six years of age or older when treated in one of the 
experimental arms compared to the control group (UFH: 18/158, 11.4%; enoxaparin: 5/120, 
4.2%, P(vs. UFH)=0.001; antithrombin 4/150, 2.7%, P(vs. UFH)<0.001). No significant 
differences were found in patients below six years of age (UFH 7/214, 3.3%; enoxaparin 
2/96, 2.1%; antithrombin 5/191, 2.6%). 
For subgroup analysis by age no formal test for interaction was done. Applying Fine-Gray 
models with interaction terms for age older than 6 years and enoxaparin/antithrombin, the 
interactions are not significant. This, however, does not entirely exclude interactions since 
the power for such tests is low. 
Hemorrhage 
Eight bleeding episodes were documented among the 929 randomized patients (0.9%). Four 
of them occurred during induction chemotherapy under antithrombotic prophylaxis and 4 
during consolidation after termination of the anticoagulants. All hemorrhages were classified 
as major (7 gastrointestinal, 1 cerebral). Four patients with hemorrhage were treated in the 
UFH group (1.1%), three in the antithrombin group (0.9%, P(vs. UFH)=1.0) and one patient in 
the enoxaparin group (0.5%, P(vs. UFH)=0.66). 
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Leukemia Outcome, Survival  
Five-year probability of EFS (5y-pEFS) and cumulative incidence of relapse (5y-CIR) of the 
THROMBOTECT cohort were comparable with the 577 non-randomized patients 
(THROMBOTECT cohort: 5y-pEFS 84.3±1.2%, 5y-CIR 11.7±1.1%; non-randomized patients: 
5y-pEFS 84.0±1.6%, 5y-CIR 11.8±1.4). Patients randomized to the antithrombin arm had a 
5y-pEFS of 80.9±2.2% compared with those assigned to the enoxaparin (86.2±2.0%, 
P=0.10) or UFH arm (85.9±2.0%, P=0.06) (Figure 3A) with a Hazard ratio of 1.40 (1.02-1.92; 
P=0.040) for the antithrombin arm versus the remaining patients. The probability of OS at 5 
years was similar in all three arms (antithrombin 89.8±1.7%, enoxaparin 90.9±1.6%, UFH 
92.4±1.5%). The differences observed in the EFS were due to a higher incidence of late 
relapses in the antithrombin group as compared to the other groups (Figure 3C); the as-
treated analyses showed no statistically significant difference between the three groups 
(Figure 3B and D; Hazard ratio antithombin vs. others: 1.16 [0.84-1.59]; P=0.37). 
Retrospective exploratory subgroup analyses revealed a higher relapse incidence of the 
antithrombin-treated patients within the medium risk group only (Figure S3 in the 
Supplementary Appendix). Multivariate Cox regression analyses on EFS were performed 
including risk group according to respective trial criteria, TEL-AML1 status, initial white blood 
cell count, age and the THROMBOTECT arm as covariates. Hazard ratios for the 
antithrombin arm were 1.38 (0.99-1.91; P=0.054) for ITT and 1.19 (0.86-1.66; P=0.269) for 
the as-treated analysis and thus comparable with those of the univariate analyses (Table S6 
in the Supplementary Appendix). 
To test for a potential dose effect of antithrombin, doses given were analyzed in patients 
treated in the antithrombin arm. Data available for 248 of 341 patients (72.7%) did not 
disclose a dose-related effect on the relapse incidence (Figure S4 in the Supplementary 
Appendix). 
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Discussion 
Reliable data on TE during induction therapy of childhood ALL are scarce. The only 
randomized interventional trial was the PARKAA trial (Prophylactic Antithrombin replacement 
in kids with ALL treated with L-asparaginase), designed to determine if there was a trend to 
efficacy and safety of antithrombin treatment but not powered to prove it.16 To our knowledge, 
no other data from adequately designed and powered studies have been available so far to  
provide sufficient evidence that would allow valid recommendations.4,5,9,19,20,23,43,44  
For the first time, the THROMBOTECT trial shows that prophylactic antithrombotic 
intervention significantly reduced TE during ALL induction therapy as compared to the control 
arm. Both interventions, enoxaparin and activity adapted AT substitution, were equally 
effective. Asparaginase induced AT deficiency is assumed to be the most important 
mechanism for the development of TE during ALL induction therapy.45 As a consequence of 
asparagine depletion, asparaginase therapy leads to intracellular retention of a misfolded 
antithrombin, resulting in acquired antithrombin deficiency.45,46 The THROMBOTECT trial 
demonstrated that maintaining the AT activity at 80% or higher throughout the induction 
phase could significantly protect patients from TE. Thus, correction of low antithrombin 
activity seems to be one effective way to prevent TE, this being consistent with clinical and 
laboratory data on antithrombin supplementation.10,16,18,19,47   
A considerable number of patients eligible for the study were not randomized. In this group 
the rate of prednisone poor-responders was significantly higher than in the THROMBOTECT 
cohort. This may be attributed to a tendency of the doctors or parents to avoid additional 
burden from interventions of an add-on trial in particular on those patients with very poor 
response during the first days of treatment. However, patient characteristics were 
comparable between the three randomization groups except for a slight underrepresentation 
of younger patients assigned to enoxaparin. Yet, the main reason not to participate was the 
refusal to accept the daily subcutaneous enoxaparin injections. Not surprisingly, the 
proportion of patients and parents refusing the assigned enoxaparin was highest in young 
children. This demonstrates not only their reluctance to receive injections but also underlines 
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a considerable drawback in practical use, irrespective of the antithrombotic efficacy of 
enoxaparin.  
Older age proved to be an important risk factor for TE as it has been reported earlier by 
others.1,13,48 The best cut-off in our data was the age of six years. Exploratory analyses 
suggested that the benefit from either experimental arm was more pronounced in older 
patients than in young children. The significant benefit in risk reduction of TE with either 
intervention, enoxaparin or antithrombin, as compared to UFH, provides a convincing 
rationale for thromboprophylaxis in this age group. For younger children, the incidence of TE 
was low and comparable in all three randomization arms. The need of a thromboprophylaxis 
in ALL patients below 6 years of age could therefore be questioned. However, the study was 
not powered for subgroup analyses and the lack of statistical difference in TE incidence 
between the treatment groups in younger children may be due to insufficient power caused 
by the patient number as well as the lower TE incidence. Furthermore, in younger children 
TE may be missed as symptoms often are subtle. This is in line with the findings of the 
PARKAA study, showing that children with symptomatic TE tend to be older than those with 
clinically asymptomatic TE.16 Even if clinically not diagnosed, asymptomatic TE may be 
associated with significant vessel occlusion.16 This, in turn, can lead to the destruction of the 
vessel wall causing long term morbidity in terms of postthrombotic syndrome, likely becoming 
apparent years after the end of ALL therapy. Whether this applies to young patients with ALL 
remains unknown.17 Future studies with sufficient statistical power are needed to ascertain if 
such interventions in small children are justified. Nevertheless, although the high proportion 
of patients who refused the allocation to the enoxaparin arm may complicate the 
interpretation of the results in this treatment arm, the reduction of TE in the global analysis 
appears to be sufficiently convincing to recommend thromboprophylaxis not only for older 
patients but for all age groups, all the more as hemorrhage is of no concern. 
Most thrombotic events occurred between induction treatment day 9 and 36, the latter 
marking the start of induction consolidation.  This confirms our experience that TE only rarely 
occurs at the time of ALL diagnosis but rather in the course of induction therapy. 
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Furthermore, not all centers were able to get a CVC inserted at the time of ALL diagnosis. 
For these reasons, thromboprophylaxis was started after the prednisone prephase on day 8 
of induction therapy. The primary objective of the THROMBOTECT trial was to evaluate 
efficacy and safety of different prophylactic antithrombotic interventions during ALL induction 
therapy. Therefore, the duration of thromboprophylaxis was limited to induction therapy until 
day 33. Some of the thromboembolic events have occurred after the end of the induction 
phase. However, only a few of these patients had already started the consolidation phase 
when the thrombosis had been diagnosed. Factors that may have contributed to these late 
thromboses could be concurrent medical issues such as infections. Given the gradual 
development of a clot, the still asymptomatic thrombosis might have started towards the end 
of induction therapy and only become symptomatic in early induction consolidation. Since 
pegylated asparaginase is presently used more frequently - in the trial AIEOP-BFM ALL 
2009, the second dose of this drug was given on day 26 of induction - late thromboses in 
induction consolidation might become more relevant as the use of pegylated asparaginase 
may lead to an extended asparagine depletion with disturbed coagulation patterns, including 
extended dysfunction of antithrombin. Irrespective of possible concomitant prothrombotic risk 
situations, the hypercoagulable state seems to remain ongoing beyond the end of induction 
therapy. Given the very low rate of hemorrhage it might therefore be advisable to extend 
thromboprophylaxis accordingly. 
The open label assignement as well as the diagnosis of TE on clinical suspicion only are 
drawbacks of the THROMBOTECT study design. However, masking the antithrombotic 
intervention would have meant that all patients of all randomization groups would have been 
given subcutaneous injections, in the UFH and AT group containing placebo. To conduct the 
study as double-blinded trial with double dummy subcutaneous injections was not considered 
feasible in a large pediatric population.  
Similar concerns apply to the primary outcome defined as TE based on clinical suspicion. 
The PARKAA study has shown a high incidence of clinically not recognized thromboses 
found by routine imaging screening.16 To overcome observer bias, various and repeated 
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routine imaging screening for vessel occlusion at all possible anatomical sites would have 
been mandatory at predefined time points. This comprises ultrasound but also magnetic 
resonance imaging which, in young children, often requires general anaesthesia. In addition, 
for the time being the appropriate time points to look for vessel occlusions is not known and 
hence the possibility of missing a thrombosis at arbitrarily chosen time points would be high. 
Exposing the children to repeated extra anaesthesia with a questionable benefit was 
considered too high an extra burden. Therefore, the study design chosen was in favour of an 
open label treatment. Imaging was performed on clinical suspicion despite the acknowledged 
inherent drawbacks.  
Evaluation of EFS and relapse rate within the THROMBOTECT randomization groups 
revealed the unexpected finding that patients randomized to the antithrombin group had a 
higher relapse incidence compared with the enoxaparin or UFH group. The differences were 
no longer obvious in the as-treated analysis being apparent in the medium risk group only. 
Although a causal relationship between the cumulative antithrombin dose and the relapse 
rate could not be established, the possibility that antithrombin substitution might affect 
leukemia outcome cannot be entirely excluded.  
 In conclusion, the THROMBOTECT study has for the first time demonstrated that activity-
targeted antithrombin replacement as well as the use of enoxaparin lead to a significant risk 
reduction for TE during ALL induction therapy when compared with low-dose UFH. Bleeding 
was of no major concern. Thromboprophylaxis during induction therapy can therefore be 
recommended for children and adolescents with ALL. The higher incidence of late relapses 
in children with medium risk ALL assigned to the antithrombin group remains to be resolved 
and leads us at the present time to recommend primarily enoxaparin. Whether 
thromboprophylaxis contributes to minimize not only clinical but also silent thrombosis and by 
that long term morbidity in terms of postthrombotic syndrome remains to be determined. The 
THROMBOTECT results provide the rationale to develop new studies, both to elucidate a 
possible impact of antithrombin on leukemia outcome and to further determine the best 
practice to prevent TE during ALL induction chemotherapy.                 3902 words (main text) 
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Table 1. Patient characteristics by thromboprophylaxis group as assigned by randomization 
 
 
total (N=949) 
N (%) 
UFH (N=312) 
N (%) 
E (N=317) 
N (%) 
AT (N=320) 
N (%) 
Study     
ALL-BFM 2000 815 (85.9) 269 (86.2) 272 (85.8) 274 (85.6) 
AIEOP-BFM ALL 2009 134 (14.1) 43 (13.8) 45 (14.2) 44 (13.8) 
Sex     
Male  537 (56.6) 173 (55.4) 183 (57.7) 181 (56.6) 
Female 412 (43.4) 139 (44.6) 133 (42.3) 139 (43.4) 
Age     
1 – < 6 years 512 (54.0) 174 (55.8) 157 (49.5) 181 (56.6) 
6 – < 10 years 188 (19.8) 57 (18.3) 72 (22.9) 59 (18.4) 
≥ 10 years 249 (26.2) 81 (26.0) 88 (27.8) 80 (25.0) 
Central venous catheter     
CVC in site 896 (94.4) 295 (94.6) 294 (93.3) 303 (95.2) 
No CVC 53 (5.6) 17 (5.4) 21 (6.7) 15 (4.8) 
WBC at diagnosis [x109/L]     
< 20 599 (63.1) 199 (63.8) 212 (66.9) 188 (58.8) 
20 - < 100 249 (26.2) 83 (26.6) 76 (24.0) 90 (28.1) 
100 - < 200 53 (5.6) 15 (4.8) 14 (4.4) 24 (7.4) 
≥ 200 47 (5.0) 15 (4.8) 14 (4.4) 18 (5.6) 
CNS status     
CNS negative  872 (91.9) 278 (89.1) 298 (94.0) 296 (92.5) 
CNS positive  30 (3.2) 14 (4.4) 6 (1.9) 10 (3.1) 
no information 47 (5.0) 20 (6.4) 13 (4.1) 14 (4.4) 
Immunophenotype     
Non-T-ALL 827 (87.1) 264 (84.6) 298 (89.0) 281 (87.8) 
T-ALL 120 (12.6)  47 (15.1) 34 (10.7) 39 (12.3) 
no information 2 (0.2) 1 (0.3) 1 (0.3) 0 (0.0) 
Genetics      
t(12;21) / TEL-AML1     
negative 722 (76.1) 235 (75.3) 245 (77.3) 242 (75.6) 
positive 199 (21.0) 65 (20.8) 63 (19.9) 71 (22.2) 
no information 28 (3.0) 12 (3.8) 9 (2.8)  7 (2.2) 
t(9;22) / BCR-ABL     
negative 924 (97.4) 303 (97.1) 309 (97.5) 312 (97.5) 
positive 25 (2.6) 9 (2.9) 8 (2.5) 8 (2.5) 
no information 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
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total (N=949) 
N (%) 
UFH (N=312) 
N (%) 
E (N=317) 
N (%) 
AT (N=320) 
N (%) 
t(4;11) / MLL-AF4     
negative 942 (99.3) 311 (99.7) 314 (99.1) 317 (99.1) 
positive 7 (0.7) 1 (0.3) 3 (0.9) 3 (0.9) 
no information 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Peripheral blast count on 
day 8 (Prednisone 
Response) 
    
< 1x109/L (PGR) 880 (92.7) 291 (93.3) 295 (93.1) 294 (91.9) 
≥ 1x109/L (PPR) 65 (6.8) 19 (6.1) 22 (6.9) 24 (7.5) 
no information 4 (0.4) 2 (0.6) 0 (0.0) 2 (0.6) 
Risk group     
SR 301 (31.7) 97 (31.1) 101 (32.1) 101 (31.8) 
MR 512 (54.0) 171 (54.8) 169 (53.7) 170 (53.5) 
HR 136 (14.3) 44 (14.1) 45 (14.3) 47 (14.8) 
MRD at end of induction      
negative 303 (31.9) 103 (33.0) 104 (32.8) 96 (30.0) 
< 5 x 10-4 316 (33.3) 107 (34.2) 113 (35.6) 96 (30.0) 
≥ 5 x 10-3 184 (19.4) 57 (18.3) 58 (18.3) 69 (21.6) 
no information 146 (15.4) 45 (14.4) 42 (13.2) 59 (18.4) 
MRD at week 12     
negative 579 (61.0) 187 (59.9) 202 (63.7) 190 (59.4) 
< 5 x 10-4 146 (15.4) 53 (17.0) 47 (14.8) 46 (14.4) 
≥ 5 x 10-3 43 (4.5) 16 (5.1) 12 (3.8) 15 (4.7) 
no information 181 (19.1) 56 (17.9) 56 (17.7) 69 (21.6) 
Randomized in induction 
in AIEOP-BFM ALL 2000* 
    
Randomized     
assigned to PDN 125 (13.2) 39 (12.5) 41 (12.9) 45 (14.1) 
assigned to DXM 136 (14.3) 45 (14.4) 45 (14.2) 46 (14.4) 
Not randomized 688 (72.5) 228 (73.1) 231 (72.9) 229 (71.6) 
 
*For details see Figure S2 in the Supplementary Appendix and Reference Möricke, Blood 
(2016).19 
Abbreviations: AT, antithrombin; CNS, central nervous system; CVC, central venous 
catheter; DXM, dexamethasone; E, enoxaparin; HR, high risk, MR, medium risk; MRD, 
minimal residual disease; PDN, prednisone; PGR, Prednisone Good-Response; PPR, 
Prednisone Poor-Response; SR, standard risk; UFH, unfractionated heparin; WBC, white 
blood cell count.  
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Figure legends: 
 
Figure 1: Consolidated Standards for Reporting of Trials (CONSORT) diagram. AT 
denotes antithrombin, E denotes enoxaparin, UFH denotes unfractionated heparin. 
 
Figure 2: Thromboembolic events according to the randomization arms. Results are 
shown by intention to treat (A, C and E) and by treatment as given (B, D and F) for the total 
cohort (A and B) and stratified by age < 6 years (C and D) and ≥ 6 years (E and F). Events 
are depicted as cumulative incidence curves. Indicated P values were calculated with the 
Fisher’s exact test. TEE denotes thromboembolic event; UFH denotes unfractionated 
heparin; OR denotes Odds ratio; CI denotes confidence interval. 
AT denotes antithrombin, E denotes Enoxaparin, TEE denotes thromboembolic events, UFH 
denotes unfractionated heparin.  
 
Figure 3: Outcome of ALL according to the THROMBOTECT randomization arms. 
Event-free survival (A and B) and cumulative incidence of relapse (C and D) are shown by 
intention to treat (A and C) and by treatment as given (B and D). Numbers of patients at risk 
in the event-free survival graphs also apply to the respective relapse incidence graphs. 5 y-
pEFS denotes 5-year probability of event-free survival; 5 y-CIR denotes 5-year cumulative 
incidence of relapse; SE denotes standard error; UFH denotes unfractionated heparin.  
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List of participating centers (principal investigator; number of patients enrolled) 
BFM Switzerland 
• Luzern, Kantonsspital Luzern, Pädiatrische Klinik, Hämatologie/Onkologie (U. Caflisch,  
J. Rischewski; n=27) 
• St. Gallen, Ostschweizer Kinderspital, Zentrum für Pädiatrische Hämatologie/Onkologie  
(J. Greiner; n=53) 
• Zürich, Universitäts-Kinderklinik, Onkologie (F. Niggli, E. Bergsträsser, N. Bodmer; n=70) 
BFM Germany 
• Augsburg, I. Kinderklinik des Klinikum Augsburg, Hämatologie/Onkologie (A. Gnekow; n=69) 
• Aachen, Kinderklinik der Medizinischen Fakultät der RWTH (R. Mertens, L. Lassay; n=40) 
• Bad Mergentheim, Caritas Krankenhaus, Kinder- und Jugendmedizin (R. Buchhorn; n=1) 
• Berlin, Charité Campus Virchow-Klinikum Berlin, Klinik für Pädiatrie mit Schwerpunkt Onkologie 
und Hämatologie (G. Henze, A. von Stackelberg; n=117) 
• Braunschweig, Städtisches Klinikum, Klinik für Kinder- und Jugendmedizin (W. Eberl; n=26) 
• Erfurt, Helios Klinikum Erfurt GmbH, Klinik für Kinder- und Jugendmedizin (A. Sauerbrey; n=30) 
• Frankfurt /Main, Klinikum der Johann Wolfgang Goethe-Universität, Zentrum für Kinder- und 
Jugendmedizin, Klinik III, Pädiatrische Hämatologie und Onkologie (T. Klingebiel; n=29) 
• Freiburg, Universitätsklinikum, Zentrum für Kinderheilkunde und Jugendmedizin, Klinik IV, 
Pädiatrische Hämatologie und Onkologie (C. Niemeyer; n=108) 
• Hannover, Medizinische Hochschule Hannover, Kinderheilkunde IV, Klinik für Pädiatrische 
Hämatologie und Onkologie (K. W. Sykora, A. Beilken; n=84) 
• Homburg/Saar, Universitätsklinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und 
Onkologie (N. Graf, H. Reinhardt; n=24) 
• Jena, Universitätsklinikum, Klinik für Kinder- und Jugendmedizin (B. Gruhn; n=1) 
• Kassel, Klinikum Kassel, Klinik für Pädiatrische Onkologie/Hämatologie (M. Natrath, n=2) 
• Kiel, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Kinder- und Jugendmedizin, 
Pädiatrische Hämatologie und Onkologie (M. Schrappe, A. Claviez; n=70) 
• Köln, Klinikum der Universität zu Köln, Kinderonkologie und –hämatologie (F. Berthold,  
D. Schwamborn; n=56) 
• Lübeck, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Kinder- und 
Jugendmedizin, Pädiatrische Hämatologie und Onkologie (P. Bucsky, M. Lauten; n=22) 
• Magdeburg, Universitätsklinikum Magdeburg, Kinderklinik, Pädiatrische Hämatologie/Onkologie 
(U. Mittler, P. Vorwerk; n=28) 
• Marburg, Universitätskinderklinik (H. Christiansen; n=2) 
• Nürnberg, Cnopf’sche Kinderklinik (W. Scheurlen; n=1) 
• Oldenburg, Klinikum Oldenburg GmbH, Zentrum für Kinder- und Jugendmedizin, Allgemeine 
Kinderheilkunde, Hämatologie/Onkologie (R. Kolb; n=69) 
• Siegen, DRK-Kinderklinik (R. Burghard; n=6)  
• Ulm, Universitätsklinik für Kinder- und Jugendmedizin (K. M. Debatin, C. F. Classen; n=9)) 
• Vechta, St. Marienhospital Vechta, Klinik für Kinder- und Jugendmedizin (J. Erkel; n=3) 
• Wolfsburg, Klinikum Wolfsburg, Klinik für Kinder- und Jugendmedizin (S. Mukodzi; n=2) 
Supplementary appendix Greiner et al. 
 
   3 
 
Figure S1. Treatment schedule of the THROMBOTECT study 
 
 
Figure S2. Treatment schedule of induction therapy in ALL-BFM 2000 and AIEOP-BFM ALL 2009 
A.  ALL-BFM 2000 
 
B. AIEOP-BFM ALL 2009 
Induction and consolidation therapy (Protocol I) was the same as in ALL-BFM 2000 except for the 
following differences: 
• Dexamethasone was given to good-risk T-ALL only; all other patients received Prednisone. 
• Pegylated E. coli L-asparaginase given on day 12 and 26 instead of native E. coli L-asparaginase 
Day 1 Day   8 12 15 18 21 24 27 30 33
Arm 1: Unfractionated heparin 2 IU/kg/h or max. 50 IU/kg/d, when CVC is in use
- For documentation purposes, measurement of anti-Xa activity (venous blood sample, not from CVC) if infusion duration
exceeds 24 h between day 16 and day 33. No dose adjustment is necessary.
Arm 2: Low molecular weight heparin (Enoxaparin) 80-100 anti-Xa units once daily s.c. 
- Measurement of anti-Xa activity on day 12 if LP on day 15, or on day 15 if LP on day 12 (venous blood sample, not from CVC)
- Target value: anti-Xa activity ≤ 0.4 IU/ml [for deviations: dose adjustment of Enoxaparin and repeat measurement of anti-Xa activity
after 3 days]
- no concomitant antithrombin replacement
Arm 3: Antithrombin (AT) replacement (KyberninR), if Antithrombin is < 80%
- Antithrombin measurement before each asparaginase dose (CVC may be used)
- Dosage according to the formula
 
AT
 nominal  (100%) - AT actual x kg
- Antithrombin can also be given on the same day, after the asparaginase 
  Enoxaparin  80-100 anti-Xa IU/kg once daily s.c.  =  0.8-1.0 mg/kg/day
AT ATAT AT ATAT AT
Th
ro
m
bo
te
ct
 
 
 
 
 
 
 
 
 
 
ra
n
do
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iz
at
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n
Pr
e
ph
a
s
e
AT
 Arm 1
Arm 2
Arm 3
   Heparin infusion 2 IU/kg/h or max. 50 IU/kg/d  (when CVC in use)
*additional i.th. MTX on days 19 and 26 if CNS-positive (CNS 3) or presence of blasts in initial cytospin (CNS 2)
PRED p.o. 60 mg/m²/day
VCR i.v. 1.5 mg/m²/dose
max. 2 mg
E. coli L-ASP p.i. (1 h) 10,000 IU/m²/dose
DNR p.i. (1 h) 30 mg/m²/dose
MTX i.th.
Age-adjusted dose:
1 to < 2 years: 8 mg
2 to < 3 years: 10 mg ≥ 
3 years: 12 mg
DEXA p.o. 10 mg/m²/day
Days 8 22 291 15 33
* *
R
36 43 50 57 64
CPM p.i. (1 h) 1000 mg/m²/dose
ARA-C i.v. 75 mg/m²/dose
6-MP p.o. (28 d) 60 mg/m²/day
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Figure S3. Relapse incidence in specific patient subsets in analysed in randomized patients 
according to the treatment as given  
A  Age < 6 years B Age ≥ 6 years 
 
C   Risk group SR (Standard Risk) D Risk group MR (Medium Risk) 
 
E  Risk group HR (High Risk)  
 
 
P values were calculated with the Gray’s test. 
Abbreviations: 5 y-CIR, 5-year cumulative incidence of relapse; SE, standard error; UFH, 
unfractionated heparin. 
  
N 5 y-CIR SE relapses
UFH given 214 10.6 % 2.2 % 24
Enoxaparin given 96 6.4 % 2.5 % 7
Antithrombin given 191 12.7 % 2.4 % 27
UFH vs. enoxaparin P = 0.27
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Enoxaparin vs. antithrombin P = 0.09
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Figure S4. Relapse incidence of randomized patients treated in the antithrombin arm according to 
the cumulative antithrombin dose actually substituted per KG body weight 
 
The P value was calculated with the Gray’s test. 
Abbreviations: 5 y-CIR, 5-year cumulative incidence of relapse; SE, standard error. 
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Table S1. Recommended diagnostic procedures for suspected thrombosis 
Suspected diagnosis Diagnostic procedures 
Deep vein thrombosis Conventional and/or pulse-wave ultrasound, and/or color Doppler 
ultrasound, if not conclusive  phlebography 
Sinus vein thrombosis (angio)magnetic resonance imaging 
Atrial thrombosis Echocardiography 
Catheter occlusion Imaging of the catheter tip using contrast medium (Note: identifies only 
thrombi at the tip of the central venous catheters (CVC), does not 
identify thrombi along the intravascular part of the catheter (sheath clot). 
If strong clinical suspicion of CVC-related thrombosis, perform 
phlebography) 
Pulmonary embolism (Ventilation) perfusion scintigraphy  
Abbreviations: ALL, acute lymphoblastic leukemia 
Table S2. Definition of major and minor haemorrhage [1-3] 
Major hemorrhage  This category covers hemorrhages meeting one or more of the following 
criteria: 
• clinically evident 
• fatal 
• requiring erythrocyte replacement (10-20 ml/kg body weight) 
• hemorrhage located within the cranium/spine, or eye, or 
retroperitoneum (diagnosis using magnetic resonance imaging, 
computed tomography and/or ultrasound) 
• severe or life-threatening event resulting from the hemorrhage, 
therefore requiring intensive care 
Minor hemorrhage 
 
This category covers hemorrhages which, although clinically evident, do not 
meet the criteria for a major hemorrhage. 
Minor hemorrhages includes: 
• epistaxis (irrespective of platelet count) lasting more than 5 minutes, 
whether or not treatment is necessary 
• nonmechanical hematuria (i.e. not caused by urinary catheter, 
nephrolithiasis) 
• nonmechanical hemorrhages in the gastrointestinal tract (i.e. not caused 
by gastric tube, endoscopy, intubation) 
• hemorrhage of the skin and mucous membranes 
• subconjunctival hemorrhage 
• wound hematoma or minor bleeding from a new wound, as they do not 
satisfy the criteria for a major hemorrhage 
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Table S3. Patient characteristics of randomized versus eligible non-randomized patients  
 
 randomized patients 
(N=949) 
N (%) 
patients not 
randomized (N=577) 
N (%) 
P 
(Fisher’s exact) 
Study    
ALL-BFM 2000  815 (85.9) 412 (71.4) < 0.001 
AIEOP-BFM ALL 2009 134 (14.1) 165 (28.6)  
Sex    
Male  537 (56.6) 335 (58.1) 0.59 
Female  412 (43.4) 242 (41.9)  
Age    
1 – < 6 years 512 (54.0) 311 (53.9) 0.99 
6 – < 10 years 188 (19.8) 113 (19.6)  
≥ 10 years 249 (26.2) 153 (26.5)  
WBC at diagnosis [x10
9
/L]    
< 20 599 (63.1) 344 (63.4) 0.21 
20 - < 100 249 (26.2) 151 (25.6)  
100 - < 200 53 (5.6) 41 (6.0)  
≥ 200 47 (5.0) 40 (5.0)  
No information 1 (0.1) 1 (0.2)  
CNS status    
CNS negative  872 (91.9) 519 (89.9) 0.88 
CNS positive  30 (3.2) 19 (3.3)  
no information 47 (5.0) 39 (5.0)  
Immunophenotype    
Non-T-ALL 827 (87.1) 491 (85.1) 0.22 
T-ALL 120 (12.6) 86 (14.9)  
no information 2 (0.2) 0 (0.0)  
Genetics     
t(12;21) / TEL-AML1    
negative 722 (76.1) 455 (78.9) 0.36 
positive 199 (21.0) 110 (19.1)  
no information 28 (3.0) 12 (2.1)  
t(9;22) / BCR-ABL    
negative 924 (97.4) 559 (99.3) 0.63 
positive 25 (2.6) 18 (0.7)  
no information 0 (0.0) 0 (0.0)  
t(4;11) / MLL-AF4    
negative 942 (99.3) 573 (99.3) 1.0 
positive 7 (0.7) 4 (0.7)  
no information 0 (0.0) 0 (0.0)  
Peripheral blast count on 
day 8 (Prednisone Response) 
   
< 1x10
9
/L (PGR)
 
880 (92.7) 500 (86.7) < 0.001 
≥ 1x10
9
/L (PPR) 65 (6.8) 71 (12.3)  
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 randomized patients 
(N=949) 
N (%) 
patients not 
randomized (N=577) 
N (%) 
P 
(Fisher’s exact) 
no information 4 (0.4) 6 (1.0)  
Risk group according to 
ALL-BFM 2000 criteria 
   
 SR 301 (31.7) 178 (30.8) 0.003 
 MR 512 (54.0) 278 (48.2)  
 HR 136 (14.3) 121 (21.0)  
MRD at end of induction     
negative 303 (31.9) 140 (24.3) 0.017 
< 5 x 10
-4 
316 (33.3) 201 (34.8)  
≥ 5 x 10
-3 
184 (19.4) 126 (21.8)  
no information 146 (15.4) 110 (19.1)  
MRD at week 12    
Negative 579 (61.0) 278 (48.2) 0.013 
< 5 x 10
-4 
146 (15.4) 98 (17.0)  
≥ 5 x 10
-3 
43 (4.5) 35 (6.1)  
no information 181 (19.1) 166 (28.8)  
Abbreviations: AT, antithrombin; CNS, central nervous system; HR, high risk, MR, medium risk; MRD, 
minimal residual disease; PGR, Prednisone Good-Response; PPR, Prednisone Poor-Response; SR, 
standard risk; WBC, white blood cell count. 
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Table S4. Patient characteristics by thromboprophylaxis group as treated 
 total 
N (%) 
UFH 
N (%) 
E 
N (%) 
AT 
N (%) 
no treatm.  
N (%) 
all 949 372 216 341 20 
Study      
ALL-BFM 2000 815 (85.9) 321 (86.3) 188 (87.0) 290 (85.0) 16 (80.0) 
AIEOP-BFM ALL 2009 134 (14.1) 51 (13.7) 28 (13.0) 51 (15.0) 4 (20.0) 
Sex      
Male  537 (56.6) 202 (54.3) 136 (63.3) 189 (55.4) 10 (50.0) 
Female 412 (43.4) 170 (45.7) 80 (37.0) 152 (44.6) 10 (50.0) 
Age      
1 – < 6 years 512 (54.0) 214 (57.8) 96 (44.4) 191 (56.0) 11 (55.0) 
6 – < 10 years 188 (19.8) 68 (18.3) 53 (24.5) 65 (19.1) 2 (10.0) 
≥ 10 years 249 (26.2) 90 (24.2) 67 (31.0) 85 (24.9) 7 (35.0) 
Central venous catheter      
CVC in site 896 (94.4) 355 (95.4) 200 (92.6) 327 (95.9) 14 (70.0) 
No CVC 53 (5.6) 17 (4.6) 16 (7.4) 14 (4.1) 6 (30.0) 
WBC at diagnosis [x10
9
/L]      
< 20 599 (63.1) 247 (66.4) 135 (62.5) 205 (60.1) 12 (60.0) 
20 - < 100 249 (26.2) 94 (25.3) 57 (26.4) 93 (27.3) 5 (25.0) 
100 - < 200 53 (5.6) 16 (4.3) 10 (4.6) 24 (7.0) 3 (15.0) 
≥ 200 47 (5.0) 15 (4.0) 13 (6.0) 19 (5.6) 0 (0.0) 
CNS status      
CNS negative  872 (91.9) 337 (90.6) 203 (94.0) 315 (92.4) 17 (85.0) 
CNS positive  30 (3.2) 14 (3.8) 5 (2.3) 10 (2.9) 1 (5.0) 
no information 47 (5.0) 21 (5.6) 8 (3.7) 16 (4.7) 2 (10.0) 
Immunophenotype      
Non-T-ALL 827 (87.1) 321 (86.3) 189 (87.5) 301 (88.3) 16 (80.0) 
T-ALL 120 (12.6) 49 (13.2) 27 (12.5) 40 (11.7) 4 (20.0) 
no information 2 (0.2) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 
Genetics       
t(12;21) / TEL-AML1      
negative 722 (76.1) 279 (75.0) 170 (78.7) 258 (75.7) 15 (75.0) 
positive 199 (21.0) 78 (21.0) 40 (18.5) 76 (22.3) 5 (25.0) 
no information 28 (3.0) 0 (0.0) 15 (4.0) 6 (2.8) 7 (2.1) 
t(9;22) / BCR-ABL      
negative 924 (97.4) 361 (97.0) 210 (97.2) 333 (97.7) 20 (100.0) 
positive 25 (2.6) 11 (3.0) 6 (2.8) 8 (2.3) 0 (0.0) 
no information 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
t(4;11) / MLL-AF4      
negative 942 (99.3) 370 (99.5) 215 (99.5) 338 (99.1) 19 (95.0) 
positive 7 (0.7) 2 (0.5) 1 (0.5) 3 (0.9) 1 (5.0) 
no information 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Peripheral blast count on 
day 8 (Prednisone Response) 
     
< 1x10
9
/L (PGR) 880 (92.7) 349 (93.8) 198 (91.7) 314 (92.1) 19 (95.0) 
≥ 1x10
9
/L (PPR) 65 (6.8) 21 (5.6) 18 (8.3) 25 (7.3) 1 (5.0) 
no information 4 (0.4) 2 (0.5) 0 (0.0) 2 (0.6) 0 (0.0) 
Risk group      
SR 301 (31.7) 118 (31.7) 66 (30.6) 112 (32.8) 5 (25.0) 
MR 512 (54.0) 202 (54.3) 117 (54.2) 180 (52.8) 13 (65.0) 
HR 136 (14.3) 52 (14.0) 33 (15.3) 49 (14.4) 2 (10.0) 
MRD at end of induction       
negative 303 (31.9) 127 (34.1) 66 (30.6) 103 (30.2) 7 (35.0) 
< 5 x 10
-4 
316 (33.3) 126 (33.9) 81 (37.5) 103 (30.2) 6 (30.0) 
≥ 5 x 10
-3 
184 (19.4) 67 (18.0) 41 (19.0) 72 (21.2) 4(20.0) 
no information 146 (15.4) 52 (14.0) 28 (13.0) 63 (18.5) 3 (15.0) 
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 total 
N (%) 
UFH 
N (%) 
E 
N (%) 
AT 
N (%) 
no treatm.  
N (%) 
MRD at week 12      
Negative 579 (61.0) 228 (61.3) 136 (63.0) 206 (59.5) 12 (60.0) 
< 5 x 10
-4 
146 (15.4) 61 (16.4) 35 (16.2) 48 (14.1) 2 (10.0) 
≥ 5 x 10
-3 
43 (4.5) 18 (4.8) 9 (4.2) 16 (4.7) 0 (0.0) 
no information 181 (19.1) 65 (17.5) 36 (16.7) 74 (21.7) 0 (0.0) 
Randomized in induction in 
AIEOP-BFM ALL 2000* 
     
Randomized      
assigned to PDN
 
125 (13.2) 54 (14.5) 22 (10.2) 47 (13.8) 2 (10.0) 
assigned to DXM 136 (14.3) 58 (15.6) 31 (14.4) 44 (12.9) 3 (15.0) 
Not randomized 688 (72.5) 260 (69.9) 163 (75.5) 250 (73.3) 15 (75.0) 
 
*For details see Fig S2 in the Supplementary Appendix and Reference Möricke, Blood (2016).
19 
Abbreviations: AT, antithrombin; CNS, central nervous system; CVC, central venous catheter; DXM, 
dexamethasone; E, enoxaparin; HR, high risk, MR, medium risk; MRD, minimal residual disease; PDN, 
prednisone; PGR, Prednisone Good-Response; PPR, Prednisone Poor-Response; SR, standard risk; 
UFH, unfractionated heparin; WBC, white blood cell count.  
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Table S5. Randomly assigned versus given treatment with respect to age groups  
 
  Arm as treated 
 All patients 
N (%) 
UFH 
N (%) 
Enoxaparin 
N (%) 
Antithrombin 
N (%) 
No treatment 
N (%) 
Age < 6 years      
All patients 512 (100.0) 214 (41.8) 96 (18.8) 191 (37.3) 11 (2.1) 
Arm as assigned      
UFH 174 (100.0) 169 (97.1) 0 (0.0) 2 (1.1) 3 (1.7) 
Enoxaparin  157 (100.0) 43 (27.4) 95 (60.5) 14 (8.9) 5 (3.2) 
Antithrombin 181 (100.0) 2 (1.1) 1 (0.6) 175 (96.7) 3 (2.1) 
Age ≥ 6 years      
All patients 437 (100.0) 158 (36.2) 120 (27.5) 150 (34.3) 9 (2.1) 
Arm as assigned      
UFH 138 (100.0) 133 (96.4) 3 (2.2) 0 (0.0) 2 (1.4) 
Enoxaparin  160 (100.0) 23 (14.4) 117 (73.1) 16 (10.0) 4 (2.5) 
Antithrombin 139 (100.0) 2 (1.4) 0 (0.0) 134 (96.4) 3 (2.2) 
Abbreviations: UFH, unfractionated heparin 
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Table S6. Multivariate Cox regression analyses on leukemia-related event-free survival in the randomization groups by intention to treat and as 
treated 
 THROMBOTECT arms by intention to treat  THROMBOTECT arms as treated 
 N (%) 
 
Hazard ratio 95% CI P 
 
 
N (%) 
 
Hazard ratio 95% CI P 
Risk group            
 SR 293 (31.9)  0.44 0.28-0.71 0.001  288 (32.0)  0.43 0.27-0.70 0.001 
 MR 496 (53.9)  1    483 (53.7)  1   
 HR 131 (14.2)  1.62 1.10-2.40 0.015  129 (14.3)  1.54 1.03-2.30 0.034 
TEL-AML1            
 negative 721 (78.4)  1    706 (78.4)  1   
 positive 199 (21.6)  0.54 0.32-0.93 0.026  194 (21.6)  0.57 0.34-0.99 0.044 
WBC (x10
9
/L)            
 < 50 718 (78.0)  1    702 (78.0)  1   
 ≥ 50 202 (22.0)  1.30 0.91-1.86 0.146  198 (22.0)  1.38 0.96-1.97 0.082 
Age            
 < 6 years 495 (53.8)  1    484 (53.8)  1   
 6 - < 10 years 183 (19.9)  0.80 0.50-1.28 0.351  181 (20.1)  0.85 0.53-1.36 0.500 
 ≥ 10 years 242 (26.3)  1.31 0.91-1.89 0.147  235 (26.1)   1.36 0.93-1.98 0.110 
THROMBOTECT arm        
 
   
 UFH/enoxaparin 607 (66.0)  1    566 (62.9)  1   
 antithrombin 313 (34.0)  1.38 0.99-1.91 0.054  334 (37.1)  1.19 0.86-1.66 0.296 
Supplementary appendix Greiner et al. 
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Abstract 
Thromboembolism is a serious complication of induction therapy for childhood acute 
lymphoblastic leukemia. We prospectively compared efficacy and safety of antithrombotic 
interventions in the consecutive leukemia trials ALL-BFM 2000 and AIEOP-BFM ALL 2009. 
Patients with newly diagnosed acute lymphoblastic leukemia (n=949, age 1 to 18 years) were 
randomized to receive low-dose unfractionated heparin, prophylactic low-molecular-weight 
heparin (enoxaparin) or activity-adapted antithrombin throughout induction therapy. Primary 
objective was to test whether enoxaparin or antithrombin reduce the incidence of 
thromboembolism as compared to unfractionated heparin. Principal safety outcome was 
hemorrhage; leukemia outcome was a secondary endpoint. Thromboembolism occurred in 
42 patients (4.4%). Patients assigned to unfractionated heparin had a higher risk of 
thromboembolism (8.0%) compared with those randomized to enoxaparin (3.5%; P=0.011) or 
antithrombin (1.9%; P<0.001). The proportion of patients who refused antithrombotic 
treatment as allocated was 3% in the unfractionated heparin or antithrombin, and 33% in the 
enoxaparin arm. Major hemorrhage occurred in eight patients (no differences between the 
groups). 5-year-event free survival was 80.9±2.2% if assigned to antithrombin compared to 
85.9±2.0% in the unfractionated heparin (P=0.06), and 86.2±2.0% in the enoxaparin group 
(P=0.10). In conclusion, prophylactic use of antithrombin or enoxaparin significantly reduced 
thromboembolism. Despite the considerable number of patients rejecting the assigned 
treatment with subcutaneous injections, the result remains nonambiguous. 
Thromboprophylaxis - for the present time primarily with enoxaparin - can be recommended 
for children and adolescents with acute lymphoblastic leukemia during induction therapy. 
Whether and how antithrombin may affect leukemia outcome remains to be determined.  
 
247 words (abstract) 
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Introduction 
Thromboembolism (TE) is a serious complication of glucocorticoid and E. coli asparaginase-
containing induction therapy for childhood acute lymphoblastic leukemia (ALL). Reported 
incidences vary between 1 and 37%, depending on study design and definition of 
thrombosis, as well as diagnostic, supportive and therapeutic methods.1-6 Acquired 
antithrombin deficiency as a result of asparaginase-induced asparagine depletion is 
considered to be a crucial mechanism for the development of TE during ALL induction 
therapy. The presence of a central venous catheter (CVC) seems to be an additional – at 
least local – risk factor for TE as a significant proportion of TE during ALL treatment is related 
to an indwelling CVC. Furthermore, the risk of TE has been shown to be associated with 
CVC location and insertion technique.1,5,7-12 Published data also provide good evidence for 
adolescent age to be an important risk factor for TE whereas the additional impact of 
inherited thrombophilia has been discussed controversially in the context of childhood ALL 
treatment.5,13-16  
Sufficiently powered randomized trials on thromboprophylaxis in children during ALL 
induction therapy have not been available,16-23 and evidence for the benefit of specific 
thromboprophylactic measures has therefore been lacking so far. In the absence of valid 
medical standards of care regarding thromboprophylaxis and the use of a CVC during ALL 
induction, various different approaches existed in the pediatric cancer centers in Switzerland 
and Germany in the early 2000s, each based on individual experiences and institutional 
standards. This unsatisfactory situation gave the impetus to initiate the THROMBOTECT 
trial, a prospective randomized study to evaluate the efficacy and safety of antithrombotic 
prophylaxis in children treated for ALL. 
As drug administration through an indwelling CVC provides significant gain in comfort for the 
patients and increases the safety of therapy with tissue-toxic agents, the THROMBOTECT 
study was initially designed to include patients with implanted CVC from the initiation of the 
induction phase and was only later on also opened for patients without CVC. Two 
mechanisms of action to prevent TE were utilized in the two interventional arms of the trial: 
HAEMATOL/2018/194175/final manuscript/20180926    Greiner et al. 
5 
 
inhibition of thrombin through inactivation of the coagulation factor X by the treatment with 
low-molecular weight heparin (LMWH) enoxaparin (ClexaneTM) and replacement of 
antithrombin by the plasma-derived antithrombin preparation KyberninTM to compensate for 
asparaginase-related aquired antithrombin deficiency. Being aware of the published data of 
Nowak-Göttl et al., that reported an almost 50% incidence of TE among ALL patients with a 
prothrombotic defect, and considering the additional risk factor of an indwelling CVC, a 
control arm without any intervention appeared difficult to justify.15 The third arm therefore 
included continuous infusion of low-dose unfractionated heparin (UFH) while the CVC was in 
use, with the aim to locally prevent clot formation at the tip of the catheter and hereby 
preventing thrombotic occlusion of the indwelling CVC, without reaching relevant systemic 
anticoagulatory effects.7,24-27 Therefore, the low-dose UFH was considered the control arm. 
The current report presents the clinical results of the THROMBOTECT study with respect to 
the incidence of symptomatic TE and hemorrhage as primary efficacy and safety outcomes 
as well as the secondary safety outcome of leukemia-related survival. 
 
Methods 
Study Design  
THROMBOTECT was an open-label, prospective, randomized, multicenter study to evaluate 
two different preventive antithrombotic measures during induction chemotherapy in children 
with ALL treated according to ALL-BFM 2000 (NCT 00430118) and AIEOP-BFM-ALL 2009 
treatment protocols (NCT 01117441). THROMBOTECT was an add on-study to the ALL-
BFM protocols and approved by the leading ethics committees of the Medical School 
Hannover, Germany, and St. Gallen, Switzerland, and by the local ethics committees of each 
participating site. Written informed consent was obtained from guardians and/or patients 
before randomization. The detailed study protocol is available online with the supplemental 
material. 
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Patient eligibility 
Patients were eligible if treated on the ALL-BFM 2000 or AIEOP-BFM ALL 2009 protocol28-30 
and having a CVC inserted by day 8 of induction and remaining in place at least until day 33. 
The choice of the CVC and its maintenance was at the treating physician’s discretion 
according to institutional guidelines. In August 2004, the protocol was amended to allow 
participation of patients without CVC. Exclusion criteria were known hemorrhagic disorders 
unrelated to leukemia, active gastrointestinal ulcer, previous cerebrovascular accident and/or 
known hypersensitivity to heparin.  
 
Randomization and Study Treatment  
After written informed consent had been given, randomization was performed by day 8 in a 
1:1:1 ratio using permuted blocks of 6 patients and stratified by country and the 
glucocorticoid preparation (dexamethasone or prednisone) administered during induction.29 
Randomization was centrally performed by the ALL-BFM study coordination center using 
computer-generated random number lists. This ensured that the participating centers had no 
access to the allocation sequence. The assigned arm was submitted to the centre by fax. 
Patients were randomly assigned to receive one of the two experimental thromboprophylactic 
treatments with either LMWH enoxaparin or with activity-adjusted antithrombin or to the 
control arm low-dose unfractionated heparin (UFH).  
Thromboprophylaxis was started on day 8 and ended on day 33 of induction chemotherapy 
(Figure S1 in the Supplementary Appendix). The observation period covered the induction 
and consolidation phase (Figure S2 in the Supplementary Appendix) up to and including 
protocol day 64.  
Patients in the enoxaparin group received ClexaneTM at 80-100 IU/kg body weight once daily 
subcutaneously31-34 with a target anti-Xa level not exceeding 0.4 U/l, measured 4 hours after 
the third or fourth injection. On days with lumbar puncture or other invasive procedures, 
enoxaparin was postponed until at least 4 hours after the procedure. In the case of 
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thrombocytopenia <30 x 109/L, platelet tranfusion was required or enoxaparin had to be held 
until platelet regeneration.  
In the antithrombin group, antithrombin activity was measured every three days prior to each 
asparaginase administration. If activity was below the lower limit of normal of 80%, the 
plasma-derived antithrombin preparation KyberninTM was substituted calculating the dose 
according to the formula [antithrombintarget 100% – antithrombinactual] x kg body weight targeting 
at 100% AT activity.  
Patients assigned to the control arm received UFH at 2 IU/kg body weight/hour as long as an 
infusion drip was running to locally prevent thrombotic occlusion of the indwelling CVC.24  
Treatment with coagulation factors or anticoagulants beyond the interventions intended per 
protocol was not allowed unless clinically indicated. Management of TE was at the discretion 
of the treating physician. 
Outcome Measures 
Diagnosis of TE was based upon clinical suspicion and had to be confirmed by one or more 
suitable imaging methods within routine diagnostic work-up (Table S1 in the Supplementary 
Appendix). No systematic provision was made for blinding the attending physicians or 
radiologists to the randomization arm. Intermittent dysfunction of the CVC by a clot at the tip 
of the catheter was not considered a thrombotic event as long as CVC patency was restored. 
The principal safety outcome was absence of bleeding complications during the study period. 
The definition of major and minor hemorrhage met internationally defined standards (Table 
S2 in the Supplementary Appendix).35-37 Secondary safety outcomes were event-free survival 
(EFS) and overall survival (OS). EFS was defined as time from diagnosis to the date of last 
follow-up or first event. Events were resistance to therapy, leukemia relapse, secondary 
neoplasm or death from any cause. Failure to achieve remission due to early death or 
resistance was considered as event at time zero. Survival was defined as time from 
diagnosis to the date of last follow-up or death from any cause.  
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Statistical Analysis 
The primary objective was to test whether antithrombotic prophylaxis with enoxaparin or 
antithrombin was superior to UFH. The null hypothesis was that there was no difference 
between enoxaparin or antithrombin versus UFH tested with one-tailed Fisher’s exact test at 
a significance level of P=0.025 each. The main analysis was by intention-to-treat (ITT). In 
order to reach a power of 85% with a significance level of 0.025, 315 patients had to be 
randomized per group, assuming an event rate of 9% within the UFH group and 3% in the 
two interventional groups, respectively. If both comparisons were significantly different, the 
thrombosis rates in the enoxaparin and antithrombin arm had to be tested for equivalence 
(secondary objective). Antithrombin replacement and enoxaparin therapy would be 
considered equivalent if the two-sided 95% confidence interval (95%-CI) of the incidence 
difference did not exceed ±4%. For the equivalence test, patients were analyzed according to 
the given treatment (as treated).  
The Kaplan-Meier method38 was used to estimate survival rates, and differences were 
compared with the log-rank test.39 Cox proportional hazards model was used in univariate 
and multivariate survival analyses.40 Cumulative incidence functions for competing events 
were constructed by the method of Kalbfleisch and Prentice41 and compared with the Gray’s 
test.42 Odds ratios were calculated to compare the risks of thromboembolic events. Except 
for the confirmative analyses of the primary study question, all other analyses were 
exploratory. 
 
Results 
Patient Characteristics 
From December 1st, 2002, to December 31st, 2011, 1526 patients with ALL treated at one of 
the 26 study centers in Germany and Switzerland were eligible for randomization (Figure 1). 
Of these, 577 patients were not randomized, the vast majority because patients and/or 
parents refused consent to be randomized for the enoxaparin arm as they strictly did not 
wish to accept a daily subcutaneous injection. 949 patients (ITT population) were randomly 
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assigned to receive either UFH (N=312), enoxaparin (N=317) or antithrombin (N=320). 
Randomized and non-randomized eligible patients did not differ with respect to their initial 
patient characteristics (Table S3 in the Supplementary Appendix). The proportion of patients 
with poor response to the prednisone prephase (prednisone poor-responders) and slow 
treatment response as assessed by minimal residual disease was significantly higher in the 
group of non-randomized patients. In the ITT population, numbers and characteristics of 
patients were well balanced between the three randomization arms except for a slight 
imbalance in the age distribution with fewer children below six years in the enoxaparin group 
(Table 1). Patient characteristics were evenly distributed between the randomization arms as 
treated except for a significantly lower proportion of patients below 6 years of age in the 
enoxaparin arm (details provided in Table S4 in the Supplementary Appendix). 
The proportion of patients who refused antithrombotic treatment as allocated was 3% in 
patients randomized to UFH (10/312) or antithrombin (11/320), and 33% (105/317) in those 
assigned to enoxaparin (Figure 1). Rejection of the enoxaparin arm was more frequent in 
patients below six years of age than in older patients (62/157 [39%] vs. 42/160 [27%]) with a 
preferential switch to UFH in the younger cohort (Table S5 in the Supplementary Appendix). 
Based on this finding additional exploratory analyses with respect to TE rate and leukemia-
related outcomes were therefore performed, stratified by age and in the as-treated groups. 
Thromboembolic Events 
Among the 949 randomized patients, 42 thromboembolic events were observed (4.4%; 95%-
CI 3.2 to 5.9). Of those, 20 events (47.6%) occurred in the upper, seven (16.7) in the lower 
deep venous system, and 13 (30.9%) in the cerebral sinus veins; two patients (4.8%) had a 
cerebral arterial stroke. Eight of the 42 TEE (19%) were distant to the site of the CVC. Thirty-
three events occurred between treatment day 9 and 36 during induction therapy, nine events 
between treatment day 37 and 52 of induction consolidation.  
Children below six years of age had a significantly lower risk of TE (14/512, 2.7%) than those 
aged 6 to 9 years (11/188, 5.9%) or 10 years and older (17/249, 6.8%; P=0.018). Other 
patient characteristics and features, such as gender, initial white blood cell count, 
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immunophenotype or treatment response did not influence the incidence of TE (data not 
shown). 
The incidence of TE was significantly higher in patients randomized to UFH (25/312; 8.0%) 
than in the enoxaparin (11/317; 3.5%; P=0.011) or antithrombin group (6/320; 1.9%; 
P<0.001). The as-treated analysis revealed an incidence of 6.7% in the UFH group (25/372) 
compared to 3.2% in the enoxaparin (7/216; P=0.089) and 2.6% in the antithrombin group 
(9/341; P=0.013). The respective cumulative incidences are depicted in Figures 2A and B. 
The difference between TE incidences in the enoxaparin and antithrombin group as treated 
was -0.6%; the lower and upper limit of the 95%-CI were -3.5% and +2.3%, respectively (p-
values for the corresponding one sided tests P=0.01 and P=0.001). Thus, antithrombin and 
enoxaparin were equally effective. 
Exploratory as-treated analyses stratified by age (Figures 2D and F) demonstrated a 
significantly reduced risk of TE in patients six years of age or older when treated in one of the 
experimental arms compared to the control group (UFH: 18/158, 11.4%; enoxaparin: 5/120, 
4.2%, P(vs. UFH)=0.001; antithrombin 4/150, 2.7%, P(vs. UFH)<0.001). No significant 
differences were found in patients below six years of age (UFH 7/214, 3.3%; enoxaparin 
2/96, 2.1%; antithrombin 5/191, 2.6%). 
For subgroup analysis by age no formal test for interaction was done. Applying Fine-Gray 
models with interaction terms for age older than 6 years and enoxaparin/antithrombin, the 
interactions are not significant. This, however, does not entirely exclude interactions since 
the power for such tests is low. 
Hemorrhage 
Eight bleeding episodes were documented among the 929 randomized patients (0.9%). Four 
of them occurred during induction chemotherapy under antithrombotic prophylaxis and 4 
during consolidation after termination of the anticoagulants. All hemorrhages were classified 
as major (7 gastrointestinal, 1 cerebral). Four patients with hemorrhage were treated in the 
UFH group (1.1%), three in the antithrombin group (0.9%, P(vs. UFH)=1.0) and one patient in 
the enoxaparin group (0.5%, P(vs. UFH)=0.66). 
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Leukemia Outcome, Survival  
Five-year probability of EFS (5y-pEFS) and cumulative incidence of relapse (5y-CIR) of the 
THROMBOTECT cohort were comparable with the 577 non-randomized patients 
(THROMBOTECT cohort: 5y-pEFS 84.3±1.2%, 5y-CIR 11.7±1.1%; non-randomized patients: 
5y-pEFS 84.0±1.6%, 5y-CIR 11.8±1.4). Patients randomized to the antithrombin arm had a 
5y-pEFS of 80.9±2.2% compared with those assigned to the enoxaparin (86.2±2.0%, 
P=0.10) or UFH arm (85.9±2.0%, P=0.06) (Figure 3A) with a Hazard ratio of 1.40 (1.02-1.92; 
P=0.040) for the antithrombin arm versus the remaining patients. The probability of OS at 5 
years was similar in all three arms (antithrombin 89.8±1.7%, enoxaparin 90.9±1.6%, UFH 
92.4±1.5%). The differences observed in the EFS were due to a higher incidence of late 
relapses in the antithrombin group as compared to the other groups (Figure 3C); the as-
treated analyses showed no statistically significant difference between the three groups 
(Figure 3B and D; Hazard ratio antithombin vs. others: 1.16 [0.84-1.59]; P=0.37). 
Retrospective exploratory subgroup analyses revealed a higher relapse incidence of the 
antithrombin-treated patients within the medium risk group only (Figure S3 in the 
Supplementary Appendix). Multivariate Cox regression analyses on EFS were performed 
including risk group according to respective trial criteria, TEL-AML1 status, initial white blood 
cell count, age and the THROMBOTECT arm as covariates. Hazard ratios for the 
antithrombin arm were 1.38 (0.99-1.91; P=0.054) for ITT and 1.19 (0.86-1.66; P=0.269) for 
the as-treated analysis and thus comparable with those of the univariate analyses (Table S6 
in the Supplementary Appendix). 
To test for a potential dose effect of antithrombin, doses given were analyzed in patients 
treated in the antithrombin arm. Data available for 248 of 341 patients (72.7%) did not 
disclose a dose-related effect on the relapse incidence (Figure S4 in the Supplementary 
Appendix). 
 
 
HAEMATOL/2018/194175/final manuscript/20180926    Greiner et al. 
12 
 
Discussion 
Reliable data on TE during induction therapy of childhood ALL are scarce. The only 
randomized interventional trial was the PARKAA trial (Prophylactic Antithrombin replacement 
in kids with ALL treated with L-asparaginase), designed to determine if there was a trend to 
efficacy and safety of antithrombin treatment but not powered to prove it.16 To our knowledge, 
no other data from adequately designed and powered studies have been available so far to  
provide sufficient evidence that would allow valid recommendations.4,5,9,19,20,23,43,44  
For the first time, the THROMBOTECT trial shows that prophylactic antithrombotic 
intervention significantly reduced TE during ALL induction therapy as compared to the control 
arm. Both interventions, enoxaparin and activity adapted AT substitution, were equally 
effective. Asparaginase induced AT deficiency is assumed to be the most important 
mechanism for the development of TE during ALL induction therapy.45 As a consequence of 
asparagine depletion, asparaginase therapy leads to intracellular retention of a misfolded 
antithrombin, resulting in acquired antithrombin deficiency.45,46 The THROMBOTECT trial 
demonstrated that maintaining the AT activity at 80% or higher throughout the induction 
phase could significantly protect patients from TE. Thus, correction of low antithrombin 
activity seems to be one effective way to prevent TE, this being consistent with clinical and 
laboratory data on antithrombin supplementation.10,16,18,19,47   
A considerable number of patients eligible for the study were not randomized. In this group 
the rate of prednisone poor-responders was significantly higher than in the THROMBOTECT 
cohort. This may be attributed to a tendency of the doctors or parents to avoid additional 
burden from interventions of an add-on trial in particular on those patients with very poor 
response during the first days of treatment. However, patient characteristics were 
comparable between the three randomization groups except for a slight underrepresentation 
of younger patients assigned to enoxaparin. Yet, the main reason not to participate was the 
refusal to accept the daily subcutaneous enoxaparin injections. Not surprisingly, the 
proportion of patients and parents refusing the assigned enoxaparin was highest in young 
children. This demonstrates not only their reluctance to receive injections but also underlines 
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a considerable drawback in practical use, irrespective of the antithrombotic efficacy of 
enoxaparin.  
Older age proved to be an important risk factor for TE as it has been reported earlier by 
others.1,13,48 The best cut-off in our data was the age of six years. Exploratory analyses 
suggested that the benefit from either experimental arm was more pronounced in older 
patients than in young children. The significant benefit in risk reduction of TE with either 
intervention, enoxaparin or antithrombin, as compared to UFH, provides a convincing 
rationale for thromboprophylaxis in this age group. For younger children, the incidence of TE 
was low and comparable in all three randomization arms. The need of a thromboprophylaxis 
in ALL patients below 6 years of age could therefore be questioned. However, the study was 
not powered for subgroup analyses and the lack of statistical difference in TE incidence 
between the treatment groups in younger children may be due to insufficient power caused 
by the patient number as well as the lower TE incidence. Furthermore, in younger children 
TE may be missed as symptoms often are subtle. This is in line with the findings of the 
PARKAA study, showing that children with symptomatic TE tend to be older than those with 
clinically asymptomatic TE.16 Even if clinically not diagnosed, asymptomatic TE may be 
associated with significant vessel occlusion.16 This, in turn, can lead to the destruction of the 
vessel wall causing long term morbidity in terms of postthrombotic syndrome, likely becoming 
apparent years after the end of ALL therapy. Whether this applies to young patients with ALL 
remains unknown.17 Future studies with sufficient statistical power are needed to ascertain if 
such interventions in small children are justified. Nevertheless, although the high proportion 
of patients who refused the allocation to the enoxaparin arm may complicate the 
interpretation of the results in this treatment arm, the reduction of TE in the global analysis 
appears to be sufficiently convincing to recommend thromboprophylaxis not only for older 
patients but for all age groups, all the more as hemorrhage is of no concern. 
Most thrombotic events occurred between induction treatment day 9 and 36, the latter 
marking the start of induction consolidation.  This confirms our experience that TE only rarely 
occurs at the time of ALL diagnosis but rather in the course of induction therapy. 
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Furthermore, not all centers were able to get a CVC inserted at the time of ALL diagnosis. 
For these reasons, thromboprophylaxis was started after the prednisone prephase on day 8 
of induction therapy. The primary objective of the THROMBOTECT trial was to evaluate 
efficacy and safety of different prophylactic antithrombotic interventions during ALL induction 
therapy. Therefore, the duration of thromboprophylaxis was limited to induction therapy until 
day 33. Some of the thromboembolic events have occurred after the end of the induction 
phase. However, only a few of these patients had already started the consolidation phase 
when the thrombosis had been diagnosed. Factors that may have contributed to these late 
thromboses could be concurrent medical issues such as infections. Given the gradual 
development of a clot, the still asymptomatic thrombosis might have started towards the end 
of induction therapy and only become symptomatic in early induction consolidation. Since 
pegylated asparaginase is presently used more frequently - in the trial AIEOP-BFM ALL 
2009, the second dose of this drug was given on day 26 of induction - late thromboses in 
induction consolidation might become more relevant as the use of pegylated asparaginase 
may lead to an extended asparagine depletion with disturbed coagulation patterns, including 
extended dysfunction of antithrombin. Irrespective of possible concomitant prothrombotic risk 
situations, the hypercoagulable state seems to remain ongoing beyond the end of induction 
therapy. Given the very low rate of hemorrhage it might therefore be advisable to extend 
thromboprophylaxis accordingly. 
The open label assignement as well as the diagnosis of TE on clinical suspicion only are 
drawbacks of the THROMBOTECT study design. However, masking the antithrombotic 
intervention would have meant that all patients of all randomization groups would have been 
given subcutaneous injections, in the UFH and AT group containing placebo. To conduct the 
study as double-blinded trial with double dummy subcutaneous injections was not considered 
feasible in a large pediatric population.  
Similar concerns apply to the primary outcome defined as TE based on clinical suspicion. 
The PARKAA study has shown a high incidence of clinically not recognized thromboses 
found by routine imaging screening.16 To overcome observer bias, various and repeated 
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routine imaging screening for vessel occlusion at all possible anatomical sites would have 
been mandatory at predefined time points. This comprises ultrasound but also magnetic 
resonance imaging which, in young children, often requires general anaesthesia. In addition, 
for the time being the appropriate time points to look for vessel occlusions is not known and 
hence the possibility of missing a thrombosis at arbitrarily chosen time points would be high. 
Exposing the children to repeated extra anaesthesia with a questionable benefit was 
considered too high an extra burden. Therefore, the study design chosen was in favour of an 
open label treatment. Imaging was performed on clinical suspicion despite the acknowledged 
inherent drawbacks.  
Evaluation of EFS and relapse rate within the THROMBOTECT randomization groups 
revealed the unexpected finding that patients randomized to the antithrombin group had a 
higher relapse incidence compared with the enoxaparin or UFH group. The differences were 
no longer obvious in the as-treated analysis being apparent in the medium risk group only. 
Although a causal relationship between the cumulative antithrombin dose and the relapse 
rate could not be established, the possibility that antithrombin substitution might affect 
leukemia outcome cannot be entirely excluded.  
 In conclusion, the THROMBOTECT study has for the first time demonstrated that activity-
targeted antithrombin replacement as well as the use of enoxaparin lead to a significant risk 
reduction for TE during ALL induction therapy when compared with low-dose UFH. Bleeding 
was of no major concern. Thromboprophylaxis during induction therapy can therefore be 
recommended for children and adolescents with ALL. The higher incidence of late relapses 
in children with medium risk ALL assigned to the antithrombin group remains to be resolved 
and leads us at the present time to recommend primarily enoxaparin. Whether 
thromboprophylaxis contributes to minimize not only clinical but also silent thrombosis and by 
that long term morbidity in terms of postthrombotic syndrome remains to be determined. The 
THROMBOTECT results provide the rationale to develop new studies, both to elucidate a 
possible impact of antithrombin on leukemia outcome and to further determine the best 
practice to prevent TE during ALL induction chemotherapy.                 3902 words (main text) 
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Table 1. Patient characteristics by thromboprophylaxis group as assigned by randomization 
 
 
total (N=949) 
N (%) 
UFH (N=312) 
N (%) 
E (N=317) 
N (%) 
AT (N=320) 
N (%) 
Study     
ALL-BFM 2000 815 (85.9) 269 (86.2) 272 (85.8) 274 (85.6) 
AIEOP-BFM ALL 2009 134 (14.1) 43 (13.8) 45 (14.2) 44 (13.8) 
Sex     
Male  537 (56.6) 173 (55.4) 183 (57.7) 181 (56.6) 
Female 412 (43.4) 139 (44.6) 133 (42.3) 139 (43.4) 
Age     
1 – < 6 years 512 (54.0) 174 (55.8) 157 (49.5) 181 (56.6) 
6 – < 10 years 188 (19.8) 57 (18.3) 72 (22.9) 59 (18.4) 
≥ 10 years 249 (26.2) 81 (26.0) 88 (27.8) 80 (25.0) 
Central venous catheter     
CVC in site 896 (94.4) 295 (94.6) 294 (93.3) 303 (95.2) 
No CVC 53 (5.6) 17 (5.4) 21 (6.7) 15 (4.8) 
WBC at diagnosis [x109/L]     
< 20 599 (63.1) 199 (63.8) 212 (66.9) 188 (58.8) 
20 - < 100 249 (26.2) 83 (26.6) 76 (24.0) 90 (28.1) 
100 - < 200 53 (5.6) 15 (4.8) 14 (4.4) 24 (7.4) 
≥ 200 47 (5.0) 15 (4.8) 14 (4.4) 18 (5.6) 
CNS status     
CNS negative  872 (91.9) 278 (89.1) 298 (94.0) 296 (92.5) 
CNS positive  30 (3.2) 14 (4.4) 6 (1.9) 10 (3.1) 
no information 47 (5.0) 20 (6.4) 13 (4.1) 14 (4.4) 
Immunophenotype     
Non-T-ALL 827 (87.1) 264 (84.6) 298 (89.0) 281 (87.8) 
T-ALL 120 (12.6)  47 (15.1) 34 (10.7) 39 (12.3) 
no information 2 (0.2) 1 (0.3) 1 (0.3) 0 (0.0) 
Genetics      
t(12;21) / TEL-AML1     
negative 722 (76.1) 235 (75.3) 245 (77.3) 242 (75.6) 
positive 199 (21.0) 65 (20.8) 63 (19.9) 71 (22.2) 
no information 28 (3.0) 12 (3.8) 9 (2.8)  7 (2.2) 
t(9;22) / BCR-ABL     
negative 924 (97.4) 303 (97.1) 309 (97.5) 312 (97.5) 
positive 25 (2.6) 9 (2.9) 8 (2.5) 8 (2.5) 
no information 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
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total (N=949) 
N (%) 
UFH (N=312) 
N (%) 
E (N=317) 
N (%) 
AT (N=320) 
N (%) 
t(4;11) / MLL-AF4     
negative 942 (99.3) 311 (99.7) 314 (99.1) 317 (99.1) 
positive 7 (0.7) 1 (0.3) 3 (0.9) 3 (0.9) 
no information 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Peripheral blast count on 
day 8 (Prednisone 
Response) 
    
< 1x109/L (PGR) 880 (92.7) 291 (93.3) 295 (93.1) 294 (91.9) 
≥ 1x109/L (PPR) 65 (6.8) 19 (6.1) 22 (6.9) 24 (7.5) 
no information 4 (0.4) 2 (0.6) 0 (0.0) 2 (0.6) 
Risk group     
SR 301 (31.7) 97 (31.1) 101 (32.1) 101 (31.8) 
MR 512 (54.0) 171 (54.8) 169 (53.7) 170 (53.5) 
HR 136 (14.3) 44 (14.1) 45 (14.3) 47 (14.8) 
MRD at end of induction      
negative 303 (31.9) 103 (33.0) 104 (32.8) 96 (30.0) 
< 5 x 10-4 316 (33.3) 107 (34.2) 113 (35.6) 96 (30.0) 
≥ 5 x 10-3 184 (19.4) 57 (18.3) 58 (18.3) 69 (21.6) 
no information 146 (15.4) 45 (14.4) 42 (13.2) 59 (18.4) 
MRD at week 12     
negative 579 (61.0) 187 (59.9) 202 (63.7) 190 (59.4) 
< 5 x 10-4 146 (15.4) 53 (17.0) 47 (14.8) 46 (14.4) 
≥ 5 x 10-3 43 (4.5) 16 (5.1) 12 (3.8) 15 (4.7) 
no information 181 (19.1) 56 (17.9) 56 (17.7) 69 (21.6) 
Randomized in induction 
in AIEOP-BFM ALL 2000* 
    
Randomized     
assigned to PDN 125 (13.2) 39 (12.5) 41 (12.9) 45 (14.1) 
assigned to DXM 136 (14.3) 45 (14.4) 45 (14.2) 46 (14.4) 
Not randomized 688 (72.5) 228 (73.1) 231 (72.9) 229 (71.6) 
 
*For details see Figure S2 in the Supplementary Appendix and Reference Möricke, Blood 
(2016).19 
Abbreviations: AT, antithrombin; CNS, central nervous system; CVC, central venous 
catheter; DXM, dexamethasone; E, enoxaparin; HR, high risk, MR, medium risk; MRD, 
minimal residual disease; PDN, prednisone; PGR, Prednisone Good-Response; PPR, 
Prednisone Poor-Response; SR, standard risk; UFH, unfractionated heparin; WBC, white 
blood cell count.  
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Figure legends: 
 
Figure 1: Consolidated Standards for Reporting of Trials (CONSORT) diagram. AT 
denotes antithrombin, E denotes enoxaparin, UFH denotes unfractionated heparin. 
 
Figure 2: Thromboembolic events according to the randomization arms. Results are 
shown by intention to treat (A, C and E) and by treatment as given (B, D and F) for the total 
cohort (A and B) and stratified by age < 6 years (C and D) and ≥ 6 years (E and F). Events 
are depicted as cumulative incidence curves. Indicated P values were calculated with the 
Fisher’s exact test. TEE denotes thromboembolic event; UFH denotes unfractionated 
heparin; OR denotes Odds ratio; CI denotes confidence interval. 
AT denotes antithrombin, E denotes Enoxaparin, TEE denotes thromboembolic events, UFH 
denotes unfractionated heparin.  
 
Figure 3: Outcome of ALL according to the THROMBOTECT randomization arms. 
Event-free survival (A and B) and cumulative incidence of relapse (C and D) are shown by 
intention to treat (A and C) and by treatment as given (B and D). Numbers of patients at risk 
in the event-free survival graphs also apply to the respective relapse incidence graphs. 5 y-
pEFS denotes 5-year probability of event-free survival; 5 y-CIR denotes 5-year cumulative 
incidence of relapse; SE denotes standard error; UFH denotes unfractionated heparin.  
 
 
 



